| Autor: |
Francis Berenbaum, Jasvinder A Singh, Ali Duarte-García, Jinoos Yazdany, Pedro M Machado, Namrata Singh, Deshire Alpizar-Rodriguez, Zachary S Wallace, Eimear Duff, Rebecca Grainger, Tamer A Gheita, Elizabeth R Graef, Jean W Liew, Michael S Putman, Julia F Simard, Emily Sirotich, Carly Harrison, Philip C Robinson, Sebastian E Sattui, Jeffrey A Sparks, Gary Foster, Suleman Bhana, Wendy Costello, Jonathan S Hausmann, Paul Sufka, Richard Conway, Akpabio Akpabio, Michal Nudel, Manuel F Ugarte-Gil, Michael DiIorio, Mitchell Levine, Evelyn Hsieh, Richard A Howard, John Wallace, Inita Bulina, Kevin Kennedy, Tarin T Moni, Aman Dev Singh, Lina El Kibbi, Chieh Lo, David FL Liew, Monique Gore-Massy, Maggie J Larché, More A Kodhek, Nadine Lalonde, Laura-Ann Tomasella, Richard P Beesley, Eugenia Yupei Chock |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
RMD Open, Vol 8, Iss 2 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2056-5933 |
| DOI: |
10.1136/rmdopen-2022-002587 |
| Popis: |
Objective We investigated prolonged COVID-19 symptom duration, defined as lasting 28 days or longer, among people with systemic autoimmune rheumatic diseases (SARDs).Methods We analysed data from the COVID-19 Global Rheumatology Alliance Vaccine Survey (2 April 2021–15 October 2021) to identify people with SARDs reporting test-confirmed COVID-19. Participants reported COVID-19 severity and symptom duration, sociodemographics and clinical characteristics. We reported the proportion experiencing prolonged symptom duration and investigated associations with baseline characteristics using logistic regression.Results We identified 441 respondents with SARDs and COVID-19 (mean age 48.2 years, 83.7% female, 39.5% rheumatoid arthritis). The median COVID-19 symptom duration was 15 days (IQR 7, 25). Overall, 107 (24.2%) respondents had prolonged symptom duration (≥28 days); 42/429 (9.8%) reported symptoms lasting ≥90 days. Factors associated with higher odds of prolonged symptom duration included: hospitalisation for COVID-19 vs not hospitalised and mild acute symptoms (age-adjusted OR (aOR) 6.49, 95% CI 3.03 to 14.1), comorbidity count (aOR 1.11 per comorbidity, 95% CI 1.02 to 1.21) and osteoarthritis (aOR 2.11, 95% CI 1.01 to 4.27). COVID-19 onset in 2021 vs June 2020 or earlier was associated with lower odds of prolonged symptom duration (aOR 0.42, 95% CI 0.21 to 0.81).Conclusion Most people with SARDs had complete symptom resolution by day 15 after COVID-19 onset. However, about 1 in 4 experienced COVID-19 symptom duration 28 days or longer; 1 in 10 experienced symptoms 90 days or longer. Future studies are needed to investigate the possible relationships between immunomodulating medications, SARD type/flare, vaccine doses and novel viral variants with prolonged COVID-19 symptoms and other postacute sequelae of COVID-19 among people with SARDs. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
